-The Telegraph A low tax regime is not enough; investors need to see demonstrable action to ease the pangs of doing business in India A wave of euphoria has swept through industry and stock markets since the finance minister, Nirmala Sitharaman, announced a sharp cut in corporate tax to an effective rate of 25.17 per cent. The effective tax rate will now go down sharply from a high of 34.94 per cent,...
More »SEARCH RESULT
Total Matching Records found : 791
New government must work to improve health infrastructure -Banjot Kaur
-Down to Earth India’s GDP for health is less than 1.5 per cent and is one of the lowest in the world Health infrastructure, especially in the rural areas, is going to be one of the challenging tasks ahead for the new government. In its last tenure, it brought the Ayushman Bharat scheme — the government run health insurance programme — which was seen as a major health policy intervention. However, according...
More »Almost 90% slash in prices of nine anti-cancer drugs -Pushpa Narayan
-The Times of India CHENNAI: In a major step to make cancer cure affordable for patients and their families, the retail prices of several anti-cancer drugs, including commonly used chemotherapy injections for lung cancer treatment, have been slashed by up to 87% by the drug price control authority. After reviewing the data collected from drug manufacturers, the National Pharmaceutical Pricing Authority’s May 15 memorandum has brought nine anti-cancer drugs in its price...
More »India trashes US report, calls it attack on cheap generic drugs -Sushmi Dey
-The Times of India NEW DELHI: India has outrightly rejected allegations in a US report about the country being a chief source of counterfeit medicines to the world and said it is an attack on low cost generic drugs — crucial to make healthcare affordable. The ‘Special 301 Report’ by United States Trade Representative (USTR) slammed India and China as leading sources of counterfeit medicines distributed globally with 20% of all pharmaceutical...
More »Many essential drugs priced much higher than manufacturing cost: WHO -Sushmi Dey
-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and rare diseases are out of reach of many due to their unaffordable prices,...
More »
